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Abstract
Shigella spp. are pathogenic bacteria that cause bacillary dysentery in humans by invading
the colonic and rectal mucosa where they induce dramatic inflammation. Here, we have
analyzed the role of the soluble PRR Pentraxin 3 (PTX3), a key component of the humoral
arm of innate immunity. Mice that had been intranasally infected with S. flexneri were res-
cued from death by treatment with recombinant PTX3. In vitro PTX3 exerts the antibacterial
activity against Shigella, impairing epithelial cell invasion and contributing to the bactericidal
activity of serum.
PTX3 is produced upon LPS-TLR4 stimulation in accordance with the lipid A structure of
Shigella. In the plasma of infected patients, the level of PTX3 amount only correlates
strongly with symptom severity. These results signal PTX3 as a novel player in Shigella
pathogenesis and its potential role in fighting shigellosis. Finally, we suggest that the plasma
level of PTX3 in shigellosis patients could act as a biomarker for infection severity.
Author summary
Soluble pattern recognition molecules, PRMs, are components of the humoral arm of
innate immunity. The long pentraxin 3, PTX3, is a prototypic soluble PRM that is pro-
duced in response to primary inflammatory signals. Shigella spp. are human entero-
pathogens which invade colonic and rectal mucosa where they cause deleterious inflam-
mation. We show that PTX3 acts as an ante-antibody and contributes to the clearance of
extracellular Shigella. As a countermeasure, Shigella uses invasiveness and low-inflamma-
tory LPS to control PTX3 release in infected cells. This study highlights that the
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extracellular phase of the invasion process can be considered the “Achille heels” of Shigella
pathogenesis.
Introduction
The first line of immune defense against pathogens is guaranteed by the recognition of Patho-
gen Associated Molecular Patterns (PAMPs) by Pattern Recognition Receptors (PRRs). The
family of PRRs includes secreted, membrane-bound and cytosolic PRRs [1]. Pathogenic organ-
isms use sophisticated strategies to modulate PRR recognition and to control downstream sig-
naling. Accordingly, the human enteropathogen Shigella exploits different mechanisms to
hijack the innate immune response. The Shigella genus includes 4 serogroups: S. boydi, S. dys-
enteriae, S. flexneri and S. sonnei. and S. flexneri are the main serogroups circulating in indus-
trialized and developing countries respectively [2], but most studies centered on the invasion
process of Shigella in vitro and in vivo have been carried out with S. flexneri.
Shigella penetrates epithelial cells through a series of effectors secreted via a Type 3 Secre-
tion System (T3SS) [3] encoded by a large virulence plasmid common to all Shigella ser-
ogroups. Once inside the colonic mucosa, shigellae either fuel or dampen the inflammatory
response, depending on the step of the invasion process. In epithelial cells, Shigella multiplies
freely within the cytoplasm [4] where the cytosolic PRR Nod1 recognizes cell-wall peptidogly-
can (PGN) and activates NF-κB [5,6]. This leads to CXCL8/IL-8 production. IL-8 attracts neu-
trophils which are required for the clearance of shigellae but which also participate in the
destruction of the epithelial barrier [7]. Within epithelial cells, S. flexneri changes its lipopoly-
saccharide (LPS) structure from a highly inflammatory hexa-acylated lipid A form to a less
inflammatory tetra- and tri-acylated lipid A variant [8]. This low-inflammatory LPS is poorly
recognized by the PRR Toll-Like-Receptor 4 (TLR4), making macrophages and neutrophils
less able to control the infection. Furthermore, in B lymphocytes Shigella induces TLR2-me-
diated apoptotic death through a mechanism mediated by T3SS, independent of cell invasion
[9]. These immune evasion strategies involve TLR2 and TLR4, which are PRRs present on the
surface of many cell populations, suggesting that the extracellular step could be critical for suc-
cessful infection. To gain insight about this poorly explored aspect of Shigella pathogenesis we
analyzed the potential role of humoral PRRs, focusing on the possible involvement of Pen-
traxin 3 (PTX3), which has served as a paradigm of humoral innate immunity [10].
PTX3 is a key element of the humoral arm of innate immunity, downstream of and comple-
mentary to cellular recognition and activation. Pentraxins are an evolutionarily highly con-
served superfamily of proteins. PTX3 is the prototypic long pentraxin, while the short
pentraxins include C-reactive protein (CRP) and serum amyloid P component (SAP), acute-
phase proteins in man and mouse respectively. PTX3 is rapidly produced and released by sev-
eral cell types, e.g. mononuclear phagocytes, dendritic cells (DCs) and neutrophils [11] in
response to primary inflammatory signals (e.g. TLR engagement, TNF-α, IL-1β). PTX3 binds
selected microorganisms, including Aspergillus fumigatus, Pseudomonas aeruginosa [12, 13]
and uropathogenic Escherichia coli (UPEC) [14]. It also promotes complement activation,
thereby facilitating pathogen recognition by phagocytes [15]. All these features prompted us to
investigate whether PTX3 could play a role in Shigella pathogenesis and how and to what
extent this PRR is released upon Shigella infection. Our findings highlight that PTX3 is a new
player in the Shigella cross-talk with the infected tissues and provide novel insights into the
mechanisms of Shigella to control the production of this humoral PRR.
PTX3 tips the balance against Shigella infection
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Results
PTX3 binds to virulent S. flexneri, affects Shigella epithelial cell invasion
and macrophage internalization and contributes to serum bactericidal
activity
Firstly, we addressed the question of whether PTX3 could opsonize Shigella as reported with
A. fumigatus, Salmonella typhimurium, P. aeruginosa, Neisseria meningiditis [12,13,16] and
uropathogenic E. coli (UPEC) (14). We observed that PTX3 (50 μg/mL, 1,1 μM) opsonized the
wild type S. flexneri 5 strain M90T (Fig 1A and 1B) and its plasmidless, non-invasive variant
BS176 though to a lesser extent compared to P. aeruginosa (strain PAO1), used as a positive
control (12, 17)
Epithelial cell invasion and macrophage death [18] are hallmarks of Shigella pathogenesis.
We investigated whether PTX3 binding could affect epithelial-cell penetration by Shigella. M90T
was incubated with different concentrations of recombinant PTX3 (0.05, 0.5, 5 and 50 μg/mL)
prior to infection of HeLa cells. M90T treated with bovine serum albumin (BSA) (50 μg/mL) or
with a rabbit polyclonal antibody raised against the T3SS-invasin IpaD (50 μg/mL), which is
involved in bacterial internalization [19] was used in parallel. As shown in Figs 1C and S1A,
PTX3 opsonization with only the concentration of 50 μg/mL significantly decreased the number
of intracellular bacteria at 1 h and 2 h post-infection (p.i.) (p< 0.001: PTX3-opsonized M90T vs.
M90T plus BSA at 2h) to levels like those induced by the anti-IpaD antibody.
In human peripheral blood monocytes-derived macrophages (MoMs), opsonization with
recombinant PTX3 at same concentrations as above only determined a significant improve-
ment of bacterial phagocytosis at the concentration of 50 μg/mL (Fig 1D and 1E, S1B Fig)
(p< 0.01: PTX3-opsonized M90T vs. M90T plus BSA). Likewise, the rate of MoMs cell death,
measured through lactate dehydrogenase (LDH) release, (Fig 1F and S1C Fig) was improved
by PTX3 opsonization, as also shown with the anti-IpaD antibody [19, 20]. However, the cell
death rate followed the trend as above since it was only increased with PTX3 at the concentra-
tion of 50 μg/mL (p< 0.01: PTX3-opsonized-M90T vs.M90T plus BSA) (S1C Fig)
PTX3 is also involved in complement cascade activation and regulation [21]. There is scant
and dated literature on Shigella sensitivity to the bactericidal activity of serum [22], so we set
up a bactericidal serum assay against S. flexneri M90T. In preliminary experiments using dif-
ferent serum concentrations (10%; 13%; 17%; 67%) for 30 min at 37˚C, we found that M90T
was sensitive to concentrations of> 10% pooled normal human serum (NHS). Exposure to
17% NHS killed around 60% of bacteria (Fig 1G). Addition of low concentrations of PTX3-
5–0.5 μg/mL in the bactericidal serum assay (17% serum) significantly increased bacterial
death rate of the bacteria (Fig 1H).
In conclusion: PTX3-bound bacteria are partially impaired in their ability to invade epithe-
lial cells and are better internalized by macrophages as shown with antibody-bound bacteria
[23, 24]. Low doses of PTX3 increase the bactericidal activity of serum/complement.
Treatment with PTX3 improves survival of mice infected intranasally with
Shigella
We therefore passed to analyze a possible contribution of PTX3 in vivo, during infection. Sev-
eral reports have described the therapeutic effect of recombinant PTX3 in the models of asper-
gillosis [25, 26, 27]; of P. aeruginosa acute and chronic lung infections [17, 28, 29]; of acute
respiratory syndrome [30] and of influenza virus lung infection [31]
Mice are naturally resistant to Shigella oral infection. Therefore, alternative infection mod-
els have been developed and used [32). Among them, the intranasal route of infection in mice
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[33] has been extensively used and validated to study Shigella virulence and to analyze vaccine
candidates [32, 33]. After intranasal infection (i.n.) with virulent Shigella, mice develop a dra-
matic pneumonia and die within a few days [32, 33].
In line with these issues, we investigated whether treating mice with recombinant PTX3
could affect the outcome of intranasal infection with M90T, as shown with the other pathogens
as above. Based on previously performed pharmacokinetic analyses and therapeutic
approaches in a murine model of lung infection with A. fumigatus [12, 25, 26, 27] and P. aeru-
ginosa [17, 28, 29], we established a treatment schedule of daily intra-peritoneal (i.p.) injec-
tions with recombinant human PTX3 (0.5 mg/Kg, 11 μM) or vehicle, starting from the day of
the i.n. inoculum with 3 x 108 colony forming units (CFU) of M90T (corresponding to the
LD50 dose). The treatment with PTX3 was carried out for 48 hours (three PTX3 injections).
Following this experimental plan, we monitored animal survival/death (in three indepen-
dent experiments) during 1 week. As expected [6, 34, 35], during the 72 hours, 55% of mice
infected with M90T died (12/22) died. By contrast, the animals infected with M90T and treated
with PTX3 survived even when the treatment with PTX3 was stopped (19/19), (p< 0.0002,
two-tailed Mantel-Cox test) (Fig 2A)
At 72 h post-challenge, the bacterial load in lungs of M90T-infected animals was ~ 106 CFU
(per lung), as previously published [6, 34, 35] whereas in PTX3 treated animals the number of
CFU (per lung) was ~ 104 CFU, which was significantly (p< 0.0001) reduced with respect to
that of infected, untreated animals (Fig 2B).
The local level of pro-inflammatory cytokines and chemokines was measured in BALs
(broncho- alveolar lavage) (Fig 2C) and lung homogenates (Fig 2D). We chose some chemo-
kines/cytokines, which have been previously shown to be influenced by PTX3 treatment [12
and 17, 29] and/or to be involved in Shigella infection [6, 34, 8]. CCL5 (RANTES) and IL-1β
values were similar in BALs and lung homogenates for untreated and PTX3-treated infected
animals, while those of TNF-α CXCL2/MIP-2 and CXCL1/KC were drastically decreased in
both homogenates and BALs of PTX3-treated mice compared to infected-untreated mice (for
all, p<0.0001, two-tailed Mann-Whitney test). Furthermore, we quantified the PTX3 levels in
sera (Fig 2E), lung homogenates (Fig 2F) and BALs (Fig 2G). In lung homogenates of M90T-
only-infected animals the PTX3 level was lower than that of PTX3-treated infected and unin-
fected mice (for both, p< 0.0001 two-tailed Mann-Whitney test). Likewise, in BALs and sera
the levels of PTX3 were significantly (p< 0.0001, two-tailed Mann-Whitney test) reduced in
M90T-only-infected animals with respect to those treated with PTX3.
Fig 1. Opsonization of S. flexneri by PTX3 and downstream effects on cell populations and serum sensitivity. (A) Binding of PTX3 to S.
flexneri M90T and BS176 or P. aeruginosa (PAO1), was shown using biotin-labeled PTX3 (50 μg/mL, corresponding to 1,1 μM) or BSA (at
70 μg/mL), which was used as a control and evaluated by flow cytometry. (B) Representative flow cytometry data of three individual experiments
of binding assay shown in panel A. PTX3-opzonized-bacteria display an increased FITC staining with respect to bacteria incubated with BSA.
(C) Effect of PTX3 opsonization on HeLa cells. S. flexneri M90T was incubated for 1 h with either recombinant PTX3 (50 μg/mL, corresponding
to 1,1 μM), anti-IpaD Ab, BSA (both at 50 μg/mL) or BSA plus recombinant PTX3 as above or left in medium alone (M90T) and used to infect
HeLa cells at a multiplicity of infection (MOI) of 50. The number of bacteria per infected cell was evaluated at 1 h and 2 h of incubation post-
infection (p.i.). (D, E and F) Effect of PTX3 opsonization on human macrophages (MoMs). (D) Bacterial internalization in MoMs. M90T
(expressing GFP) treated with either recombinant PTX3 (50 μg/mL, corresponding to 1,1 μM), anti-IpaD Ab or BSA (both at 50 μg/mL) as
above was used to infect MoMs at MOI 5 for 2 h p.i. M90T incubated in medium alone was used in parallel (M90T) (E) Representative flow
cytometry data of three individual experiments of bacterial internalization in MoMs shown in panel D. The cells were stained for CD14+ (PE/Cy
5.5) and evaluated by flow cytometry. CD14+ GFP+ cells were counted as infected cells. Opzonized-bacteria display an increased CD14+ GFP+
staining with respect to untreated bacteria or bacteria treated with BSA. (F) Lactate dehydrogenase (LDH) release in supernatant of MoMs
treated as above. (G) Serum bactericidal assay: 105 CFU/mL of exponential phase M90T were treated with varying concentrations of human
serum (NHS) or heat-inactivated serum (HIS). % survival: CFU in the presence of NHS/CFU in the presence of HIS x 100. (H) Serum
bactericidal assay as in (E) in the presence of PTX3. Bacteria were exposed to NHS (17%) in the presence of varying concentrations of PTX3 and
survival was calculated as % of reduction of CFU number at 17% of NHS plus PTX3/ number of CFU at 17% NHS taken as value of 100. 0.5 μg/
mL PTX3 vs 17% serum (no PTX3) p 0.05; 5 μg/mL PTX3 vs 17%serum (no PTX3) p 0.01. Data reported are the mean values (± SEM) of three
independent experiments. (� p< 0.05; �� p< 0.01; ��� p< 0.001 with Student’s t-test).
https://doi.org/10.1371/journal.ppat.1007469.g001
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Fig 2. Effect of PTX3 treatment in Shigella lung infection. Animal mortality (A) and bacterial load (total CFU in lung) in lungs (B) of
C57BL/6 mice only infected with Shigella M90T strain (3 x 108) via intranasal route or M90T-infected-mice treated once a day (for 3 days)
PTX3 tips the balance against Shigella infection
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At macroscopic examination (S2 Fig Top), lungs of infected mice were enlarged, of rubbery
consistency, edematous and dusky red in color due to severe hyperemia. The lungs of infected
and PTX3-treated animals were macroscopically like the controls, and they appeared aerated,
pinkish and spongy.
In lungs of M90T-infected mice, hematoxylin-eosin staining showed acute pneumonia with
severe bronchoalveolitis, alveolar edema and many damaged areas in the parenchyma. Pulmo-
nary phlogosis was characterized by a severe and diffuse neutrophil infiltrate in peribronchial,
intraluminal and interstitial areas between alveoli (S2A, S2D and S2G Fig). In contrast, in
PTX3-treated infected mice, lungs conserved a physiological architecture with a moderate
inflammation of the aerated parenchyma and airways and a low and scattered neutrophilic
exudate (S2B, S2E and S2H Fig). Histopatological scores (S1 Table) confirmed these observa-
tions. Immunohistochemical staining of PTX3 in tissues of untreated M90T-infected mice
(S3A Fig) revealed a diffuse production of PTX3, due to the involvement of bronchial mucosa
cells and rare interspersed neutrophils. Strong PTX3-immunostain was observed in lung sec-
tions of PTX3-treated infected mice (S3B Fig). In uninfected PTX3-treated mice, PTX3 was
barely detectable with only a few scattered PMNs physiologically associated with the bronchial
mucus and the BALT (S3C Fig).
As oppose to the protective effect of recombinant PTX3 in the models of P. aeruginosa and
S. fumigatus lung infection, Ptx3-deficient mice showed increased mortality and lung coloniza-
tion [12, 17]. Likewise, Ptx3 -/- mice were more susceptible than the wild type to influenza
virus and to UPEC infections [31, 14]. Hence, we assessed whether deficiency of PTX3 could
affect the virulence of Shigella. With this aim Ptx3-/- mice were infected via intranasal route
with M90T as above and the animals were monitored for a week. We found that Ptx3-/- mice
challenged with M90T showed an accelerated death with respect to M90T-infected wild type
mice (p< 0.046, two-tailed Mantel-Cox test) as the majority (75%: 20/30) of the animals died
after 48 hours p.i. (Fig 3A) At a same time point, only 23% (7/30) wild type infected mice died.
The bacterial load in lungs of Ptx3-/- of the infected animals was around ten times more (9,3
x105 vs 1,54 x105) (p<0.0001, two-tailed Mann-Whitney test) than that found in infected wild
type animals (Fig 3B). Likewise, the levels of TNF-α, CXCL-1 and CXCL-2 in BALs (Fig 3C)
and lung homogenates (Fig 3D) were significantly higher (for all, p<0.0001, two-tailed
Mann-Whitney test) than those elicited in infected wild type mice.
Conclusively, these findings suggest that PTX3 is involved in Shigella pathogenesis. Never-
theless, only a genetic rescue with transgene expression or recombinant Ptx3 administration to
Ptx3-/- mice could consolidate this result.
Invasive Shigella induces lower PTX3 release by bone marrow-derived
dendritic cells (BMDCs) and monocyte derived
We then proceeded to examine whether and to what extent Shigella infection could trigger per
se PTX3 release.
with recombinant PTX3 (10 μg/mouse i.p.). In (A) n = 22 for M90T-infected-mice, n = 19 for M90T-infected and treated-mice, n = 10 for
non-infected PTX3-treated mice in three separate experiments. (p< 0.0002, two-tailed Mantel-Cox test). In (B) The lungs were removed at
72h of infection for the bacterial counts. n = 10 for M90T-infected-mice and n = 11 for M90T-infected and treated-mice, respectively; n = 10
for non-infected PTX3-treated mice Data show total CFU per lung (CFU in one lung). Dots represent CFU in individual mice, horizontal
lines represent mean values and the error bars represent the standard error of the mean (SEM) (p<0.0001, two tailed Mann-Whitney test).
(C and D): cytokine and chemokine (pg/mL) quantification in BALs (C, left) and lung homogenates (D, right); n = 10 for M90T-infected-
mice and n = 11 for M90T-infected and treated-mice, respectively; n = 10 for non-infected PTX3-treated mice. PTX3 quantification (ng/mL)
in serum (E), lung homogenates (F) and BAL (G) of C57BL/6 mice infected as above. n = as above. (p<0.0001, for TNF-α; CXCL-2 and
CXCL-1 and PTX3 in lung homogenates and BAL; p<0.0001 for PTX3 in sera, two tailed Mann-Whitney test) Data analysis was performed
with the GraphPad Prism 7.
https://doi.org/10.1371/journal.ppat.1007469.g002
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DCs are a major source of PTX3, released following triggers such as various inflammatory
cytokines or bacterial PAMPs [10]. BMDCs from C57BL/6 mice were infected with the inva-
sive strain M90T, or with the non-invasive isogenic strain BS176, lacking the virulence plas-
mid. BMDCs were infected with shigellae at the Multiplicity of Infection (MOI) of 10. PTX3
and TNF-α production was monitored in parallel at 1, 3, 6 and 18 h. post-infection (p.i)
BS176 induced a significantly higher release of PTX3 than M90T (Fig 4A), while TNF-α
release was equivalent with both strains (S4A Fig). To test if invasiveness was correlated to
PTX3 release, we introduced another non-invasive strain into our assay. M90T ΔipaB lacks the
T3SS-secreted invasin IpaB and is thus non-invasive in epithelial cells even if it can still con-
struct the T3SS machinery [19]. PTX3 release induced by M90T ΔipaB was similar to that of
BS176 (Fig 4A).
To confirm this trend, the infection protocol of BMDCs was modified to abrogate the inva-
sive phenotype of M90T and PTX3 release was measured as above. First, BMDCs were exposed
to the invasive and non-invasive strains, previously killed with gentamicin (Fig 4B). M90T-
and BS176-killed bacteria potentially could be phagocytized by DCs; however, the invasive
ability of M90T was destroyed. The release of PTX3 did not change in BMDCs infected with
killed BS176. In contrast, the PTX3 values induced by killed M90T were significantly higher
than those recorded with live M90T. Then, we prevented cell internalization of bacteria by
treating the cells with cytochalasin D, which disrupts cytoskeleton organization [36]. In con-
trast to the previous approach, here invasive and non-invasive bacteria could not be internal-
ized by the cells. Under this condition the PTX3 values induced by M90T were comparable to
those of BS176 (Fig 4C).
The two different experimental approaches are aimed differently at preventing the invasive
phenotype of virulent shigellae. However, under both conditions the internalization of live
M90T by the cells was inhibited, leading to a significant increase of PTX3 release.
Therefore, we analyzed the production of PTX3 and TNF-α in parallel in human peripheral
blood MoDCs. The difference in PTX3 release observed with invasive and non-invasive Shi-
gella strains in BMDCs was also recorded in MoDCs (Fig 4D). The trend of TNF-α release was
similar to that observed with PTX3 (S4B Fig), in contrast to observations in BMDCs where the
TNF-α production was equally induced by the two strains.
These results indicate that inhibition of cell invasion—due to either bacteria killing, defi-
ciency of virulence plasmid, or host cell cytoskeleton disruption—leads to higher PTX3 release
by human or murine DC.
Shigella induces PTX3 release mainly through Myd88 and Trif pathways in
DCs
To evaluate the signaling pathways involved in PTX3 production, we analyzed the putative
roles of factors involved in downstream TLR signaling: Myd88, Trif, Cd14 and Irf3 [37]. Infec-
tion of Myd88-/- BMDCs significantly reduced the release of PTX3 with respect to wild-type
BMDCs (Fig 4E). A similar trend was noted for TNF-α production (S4C Fig). The absence of
Trif, Irf3 or Cd14 greatly reduced the PTX3 production as shown in Fig 4F and 4G. Likewise,
Fig 3. Susceptibility of Ptx3-/- mice to M90T intranasal infection. (A) Animal mortality (n = 30 in three experiments for Ptx3-/- and C57BL/
6 mice) (p< 0.046, two tailed Mantel-Cox test) and (B) bacterial load (total CFU in one lung) in lungs (n = 10 for Ptx3-/- mice and n = 13 for
C57BL/6 mice, respectively) (at 48 h post-challenge) of Ptx3-/- and C57BL/6 mice infected with Shigella M90T strain (1 x 108) via intranasal
route. Dots represent CFU in individual mice, horizontal lines represent mean values and the error bars represent the standard error of the
mean (SEM) (p<0.0001, two tailed Mann-Whitney test). (C and D) TNF-α, CXCL-2 and CXCL-1 quantification in BALs (C, left) and lung
homogenates (D, right) of Ptx3-/- and C57BL/6 mice infected as above (n = 10 for Ptx3-/- mice and n = 13 for C57BL/6 mice, respectively)
(p<0.0001 for all data, two-tailed Mann-Whitney test). Data analysis was performed with the GraphPad Prism 7.
https://doi.org/10.1371/journal.ppat.1007469.g003
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TNF-α measures were drastically reduced but not totally abrogated in Trif-/-, Irf3-/- and Cd14 -/-
BMDCs (S4C and S4D Fig).
As LPS is the unique PAMP engaging the Myd88 and Trif pathways, we investigated
whether LPS could trigger PTX3 release, as also shown for UPEC [14].
LPS composition influences the release of PTX3 in DCs
Shigella modifies LPS composition during intracellular residence in epithelial cells [8]. Intra-
cellular bacteria possess a hypo-acylated lipid A characterized by a blend of lipid A forms;
tetra- and tri-acylated variants are more prevalent than the hexa-acylated isoform, which is the
Fig 4. Production of PTX3 by S. flexneri in C57BL/6 BMDCs and MoDCs. (A) PTX3 release in supernatant of infected BMDCs. Cells were infected with the invasive
S. flexneri strain M90T or with the non-invasive BS176 or M90T ΔipaB at MOI 10 for 1 h, 3 h, 6 h and 18 h p.i. (o/n) (B) BMDCs infected as in (A) with M90T and
BS176 previously treated with gentamicin (60 μg/mL for 1 h). (C) BMDCs treated with cytochalasin D (0.4 μg/mL for 1 h) and then infected with M90T and BS176 as
above. (D) MoDCs infected with M90T and BS176 at MOI 10 for 1 h, 3 h, 6 h and (o/n) p.i. (E, F, G) BMDCs from (E) Myd88-/-; (F) Trif-/- and Irf3-/- and (G) Cd14-/-
mice infected with M90T and BS176 as above. (H) BMDCs stimulated with 1 ng and 10 ng of LPS derived from intracellular shigellae (iLPS), shigellae grown in TSB
medium (aLPS), Shigella ΔmsbB1 ΔmsbB2 (ΔmsbB) LPS and purified commercial E. coli LPS for 12 h. (I) BMDCs infected with M90T or BS176 or M90T ΔmsbB1
ΔmsbB2 at MOI 10 as in (A). (J) MoDCs stimulated with 1 ng and 10 ng of LPSs as in (H); (K) MoDCs infected with M90T or BS176 or M90T ΔmsbB1 ΔmsbB2 at MOI
10 as in (D). Graphs show the mean ± SD of triplicate wells and are representative of three independent experiments (� p< 0.05, �� p< 0.01, ��� p< 0.001, Student’s t-
test). NI: Not infected; NS: Not stimulated.
https://doi.org/10.1371/journal.ppat.1007469.g004
PTX3 tips the balance against Shigella infection
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007469 December 7, 2018 10 / 27
main component present in LPS of M90T grown in laboratory media. M90T ΔmsbB1 ΔmsbB2
[38,8] is a M90T mutant that carries penta-acylated (86%) and tetra-acylated lipid A forms.
M90T ΔmsbB1 ΔmsbB2 is fully invasive. Purified LPS from this strain showed a low inflamma-
tory potential, in accordance with the lipid A structure [8].
We checked whether LPS composition could impact PTX3 production in DCs treated with
three Shigella LPS variants: that extracted from bacteria grown in laboratory medium [acellular
(a)LPS], that purified from intracellular bacteria [intracellular (i)LPS] and LPS of M90T
ΔmsbB1 ΔmsbB2. E. coli LPS was used in parallel. BMDCs stimulated with iLPS and M90T
ΔmsbB1 ΔmsbB2 LPS produced a lower level of PTX3 with respect to aLPS and E. coli LPS,
consistent with the degree of lipid A acylation (Fig 4H). TNF-α release reflected the differences
between the LPSs (S4E Fig). Then, we examined whether the composition of LPS on live bacte-
ria could affect PTX3 yield using M90T and M90T ΔmsbB1 ΔmsbB2 in an invasion assay as
above. However, PTX3 and TNF-α release were similar for M90T and M90T ΔmsbB1 ΔmsbB2,
despite different lipid A composition (Fig 4I and S4F Fig).
MoDCs were stimulated with the three Shigella LPS forms (aLPS, iLPS and M90T ΔmsbB1
ΔmsbB2 LPS) following the scheme described for BMDCs. PTX3 yield drastically decreased
with iLPS and LPS of M90T ΔmsbB1 ΔmsbB2 with respect to aLPS (Fig 4J) and TNF-α release
followed the same trend (S4G Fig). In contrast with results in BMDCs and in accordance with
Lipid A composition, the amount of PTX3 and of TNF-α in infected MoDCs was lower with
M90T ΔmsbB1 ΔmsbB2 than with M90T (Fig 4K and S4H Fig).
Thus, in addition to invasiveness, LPS composition plays a pivotal role in triggering PTX3
release in human DCs. The effect of acylation degree of LPS on live bacteria was not evident in
murine DCs (Fig 4I vs Fig 4K) in line with the different TLR4 lipid A-sensitivity, as reported
[39,40].
LPS composition governs PTX3 production in Shigella-infected BMDMs
via the synergic action of Myd88 and Trif pathways
As macrophages are a further source of PTX3 during infections, we analyzed whether Shigella
could promote PTX3 release in macrophages, as shown in DCs.
In mouse BMDMs infected with M90T or BS176, the difference in PTX3 yield between
M90T and BS176 was like that observed in BMDCs (Fig 5A). TNF-α release did not follow this
trend as the release of this cytokine was similar between the two strains (S5A Fig). However, it
has been reported that Shigella-infected macrophages are poorly responsive to Shigella infec-
tion in the absence of an adequate pre-stimulation [41].
We then infected LPS-primed BMDMs as described previously [8] to evaluate the influence
of LPS modification on PTX3 release. BMDMs were primed with M90T aLPS (mainly hexa-
acylated), M90T iLPS (mainly tetra-acylated) and M90T ΔmsbB1 ΔmsbB2 LPS (mainly penta-
acylated) and were then infected with M90T at MOI 10. Infected BMDMs primed with iLPS
and M90T ΔmsbB1 ΔmsbB2 LPS (both LPSs hypo-acylated) released significantly less PTX3
than those primed with aLPS (Fig 5B), while the amount of TNF-α was similar for all the
LPSs, as already shown [8] (S5B Fig). Then, we stimulated the BMDMs (without infection)
with the three Shigella LPS (10 ng/mL) as above for 6 h. PTX3 and TNF-α yields were lower
with iLPS and M90T ΔmsbB1 ΔmsbB2 LPS (both LPSs hypoacylated) than with aLPS (Fig 5C
and S5C Fig). To evaluate the relative role of structural LPS on live bacteria and LPS priming,
BMDMs were primed with different LPSs and then infected with M90T ΔmsbB1 ΔmsbB2 (car-
rying a penta-acylated LPS) instead of M90T (carrying a hexa-acylated LPS) as above. PTX3
release followed the trend observed with M90T, which was consistent with the acylation degree
of the LPSs used for priming; however, M90T ΔmsbB1 ΔmsbB2 triggered a significantly lower
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release of PTX3 compared to M90T for each condition, in accordance with the hypo-acylation
degree of its LPS (Fig 5D). For TNF-α, the difference between M90T and M90T ΔmsbB1
ΔmsbB2 was maintained, while no significant difference was induced by priming with the vari-
ous LPSs as for PTX3(S5D Fig). We then examined whether MoMs (peripheral blood mono-
cyte-derived macrophages) respond to Shigella infection and LPS stimulation as observed with
BMDMs, BMDCs and MoDCs. With this aim, MoMs were infected with either: M90T, BS176,
M90T ΔmsbB1 ΔmsbB2 or stimulated with the different LPS and both PTX3 and TNF-α pro-
duction was evaluated. When infected with M90T, BS176 or M90T ΔmsbB1 ΔmsbB2, PTX3
(Fig 5E) and TNF-α yields (S5E Fig) were significantly higher with BS176 than with M90T.
This result was consistent with that seen in BMDMs, BMDC and MoDCs. Likewise, M90T
ΔmsbB1 ΔmsbB2 induced the lowest PTX3 and TNF-α production in accordance with its LPS
structure and as also observed in BMDMs and MoDCs. In MoMs stimulated with the four
forms of LPS (M90T iLPS and aLPS, M90T ΔmsbB1 ΔmsbB2 and E. coli LPS), iLPS and M90T
ΔmsbB1 ΔmsbB2 LPS induced the lowest production of PTX3 (Fig 5F) and TNF-α, just as for
BMDMs (S5F Fig).
Together, these experiments suggest that LPS composition is a major trigger of PTX3 pro-
duction in macrophages and that PTX3 production is influenced by both structural LPS on
infecting bacteria and purified LPS used for stimulation or priming.
Finally, we addressed the question about the TLR4 downstream signaling leading to PTX3
release in BMDMs as shown in BMDCs. We then used Myd88-/-, Trif-/-, Irf3-/- and Cd14-/-
BMDMs (Fig 5G) as described for BMDCs. Surprisingly, PTX3 release was abrogated in all
knockout BMDMs, indicating that the MyD88-dependent and MyD88-independent pathways
are synergistic in the production of PTX3. In accordance with published results [8] we found
that the MyD88 pathway was mainly involved in the release of TNF-α (S5G and S5H Fig),
with some contribution of the Trif pathway. In Cd14-/- BMDMs, the values of TNF-α were sig-
nificantly lower than in wild-type cells, while the absence of Irf3 did not impair TNF-α release
(S5G Fig). These results highlight some differences in the pathways leading to TNF-α and
PTX3 release.
Production of PTX3 induced by S. sonnei and level of plasma PTX3 in S.
sonnei shigellosis patients
Although S. sonnei is the main serogroup circulating in high-income countries, in recent years
S. sonnei has also been observed to prevail over S. flexneri in previously low- income countries
where socioeconomic conditions have improved [2]. We evaluated whether S. sonnei could,
like S. flexneri M90T, induce PTX3 production. BMDCs, MoDCs and BMDMs and MoMs
were infected with S. sonnei as with M90T (S6A, S6B, S6C, S6G and S6I Fig). Release of PTX3
induced by S. sonnei was similar to that induced by M90T in all cell populations. Likewise,
TNF-α was similar with both strains under all the conditions (S6D, S6E, S6F, S6H and S6J
Fig).
Fig 5. PTX3 production in S. flexneri infected C57BL/6 BMDMs and MoMs. (A) PTX3 release in supernatant of BMDMs after infection with the S.
flexneri strain M90T and its non-invasive derivative BS176 (MOI 10) at 1 h, 3 h and 6 h p.i. (B) BMDMs stimulated with 10 ng/mL of LPS derived from
intracellular shigellae (iLPS), shigellae grown in TSB medium (aLPS), M90T ΔmsbB1 ΔmsbB2 LPS (ΔmsbB) and purified commercial E. coli LPS for 4 h,
and infected with M90T (MOI 10) for 3 h p.i. (C) BMDMs after stimulation with 10 ng/mL of LPSs as in (B), at 6 h and 18 h (o/n). (D) BMDMs
stimulated with 10 ng/mL of LPSs as in (B) for 4 h, and infected with M90T ΔmsbB1 ΔmsbB2 (MOI 10) for 3 h p.i. (E) MoMs infected with Shigella
M90T, M90T ΔmsbB1 ΔmsbB2 and BS176 (MOI 0.1) for 3 h p.i. (F) MoMs after stimulation with 0.5 ng/mL of LPSs as in (B) for 12 h. (G) Myd88-/-,
Trif-/-, Irf3-/-, Cd14-/- and wild type BMDMs pre-stimulated and infected with M90T as described in (B). Graphs show the mean ± SD of triplicate wells
and are representative of three independent experiments (� p< 0.05, �� p< 0.01, ��� p< 0.001). NI: Not infected; NS: Not stimulated.
https://doi.org/10.1371/journal.ppat.1007469.g005
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The involvement of PTX3 in shigellosis prompted us to investigate PTX3 levels in plasma of
shigellosis patients. Plasma samples were collected from 31 patients in the acute stage (0–7
days after onset) of culture-proven S. sonnei shigellosis and from 19 healthy subjects and PTX3
levels were measured. Mean PTX3 levels were significantly higher in the patient group (10.4
ng/mL) compared to the control group (2.3 ng/mL) (p = 0.003). The highest levels of PTX3 in
patients and controls were 50 ng/mL and 11.75 ng/mL, respectively (Fig 6). PTX3 levels were
significantly higher within 2 days of disease onset than in samples collected later and were pos-
itively associated with signs or symptoms related to the severity of shigellosis such as body tem-
perature, number of watery stools per 24 hours and bloody stools (S2 Table). Among acute
cases of S. sonnei shigellosis whose maximal measured body temperature was above 39˚C, the
mean PTX3 level was much higher than among acute patients whose maximal measured tem-
perature was equal or below 39˚C. Similar results were found in regard to presence of blood in
stool or when both signs of severity were present, albeit reaching borderline statistical signifi-
cance (p = 0.05, p = 0.06 respectively).
Discussion
The role of the humoral arm of the innate immunity has been poorly explored in the context
of intracellular bacterial pathogens like Shigella. Here we unveil that phase fluid PRM PTX3
could play a decisive role in resolving Shigella infection as the treatment with recombinant
human PTX3 rescues animals from death in the murine model of pulmonary shigellosis. As
oppose to the protective effect of recombinant PTX3 Ptx3-/- infected mice showed a defective
ability to clear bacteria and an accelerated kinetics of death in the same infection model. This
is in line with that observed with P. aeruginosa, A. fumigatus and UPEC (12, 14, 17).
The therapeutic effect of PTX3 has already been reported for the extracellular pathogens P.
aeruginosa and A. fumigatus and Streptococcus suis [13, 17, 25, 26, 27 28, 29, 42] This PRM
influences pathogen phagocytosis through opsonization of microorganisms and by reinforcing
complement activity [11,21].
In lungs of M90T-only infected animals, bacterial load was high as reported [6, 33, 34]
while this number was significantly reduced in PTX3-treated animals. In vitro, PTX3
Fig 6. Plasma levels of PTX3 in S. sonnei shigellosis patients and healthy controls. Plasma samples obtained from
patients in the acute stage (0–7 days after onset) of culture-proven S. sonnei shigellosis and from healthy controls were
assessed for PTX3 levels. PTX3 concentrations were measured by ELISA.
https://doi.org/10.1371/journal.ppat.1007469.g006
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opsonization impairs Shigella internalization in epithelial cells, which are the replicative niche
of this pathogen. Likewise, PTX3 binds human cytomegalovirus and inhibits viral-cell fusion
and internalization, supposedly by crosslinking of glycoproteins on viral or cellular surface
[43]. PTX3 binding to Shigella might inhibit bacteria-host cell contact by interfering sterically
with the T3SS machinery thereby affecting bacterial micropinocytosis. Antibodies directed
against Shigella surface structures have been shown to prevent epithelial cell internalization
[23, 24, 44 and this study] and to promote the opsonophagocytic activity in macrophages [45].
In this light, PTX3 opsonization is reminiscent of some in vitro properties of protective anti-
bodies against Shigella external structures, thus contributing to Shigella eradication before the
adaptive immune response is mounted. These features reveal a role of PTX3 as an “ante-anti-
body” [16, 44] in Shigella infections. At a local level of infection, extracellular Shigella that are
no longer protected by the host cell cytoplasm, can be targeted by the complement system and
easily internalized by macrophages, thus improving the bacterial clearance by the tissues as we
observed in lungs of PTX3-treated mice. Indeed, Shigella is sensitive to the serum bactericidal
activity (this study), and low concentrations of PTX3 increase the killing activity of comple-
ment. It is unsurprising that PTX3 contributes to complement activity only at low concentra-
tions given that it can play a double role, either by activating the three complement pathways
or by negatively regulating them through various mechanisms, thereby limiting complement-
mediated inflammation [21].
Moreover, the architecture in lungs of M90T-only infected animals was destroyed by dra-
matic inflammation mainly characterized by a massive neutrophil infiltration. In these mice,
high levels of TNF-α and chemokines such as CXCL1 and CXCL2, which act as potent neutro-
phil chemoattractants [46], contribute to lung injury. In Ptx3-/- infected mice the inflamma-
tory response seemed to be exacerbated, as the production of TNF-α, CXCL1 and CXCL2 was
significantly higher than in wild type animals. In contrast, in lungs of PTX3-treated infected
mice low levels of CXCL1 and CXCL2 were associated with few areas filled by a neutrophilic
exudate. PTX3 can also directly contribute to local regulation of the inflammatory reaction
based on neutrophil infiltrate as it binds to the adhesion molecule P-selectin and inhibits leu-
kocyte rolling in the endothelium [47]. Although these findings sound very encouraging a
definitive result could be achieved through a genetic rescue with transgene expression in
Ptx3-/- infected mice or alternatively through administration of recombinant Ptx3 to these
animals.
In the M90T-infected wild type mice, the serum level of PTX3 was between 10 to 20 ng/mL
after 72 h of infection, which was in the range of that observed in the plasma of shigellosis
patients and in patients of aspergillosis (12). Likewise, the levels of PTX3 in BAL were in the
range of that recorded in BAL (2–10 ng/mL) of mice infected with A. fumigatus (25) or with
influenza virus (31) as both pathogens are very sensitive to the protective effect of PTX3.
These findings arise the question of whether PTX3 could play a role during natural infec-
tion in humans. In clinical trials with a S. dysenteriae 1-attenuated but still invasive vaccine, no
PTX3 increase was observed in the plasma of vaccinated individuals, [48] suggesting that only
invasion of the epithelial layer by Shigella is not sufficient to rise the amount of PTX3 at the
systemic level. In contrast to the attenuated strains, which are likely confined to the epithelial
layer, fully virulent shigellae break the integrity of the epithelial barrier and penetrate into the
mucosa where they induce severe inflammation characterized by a huge amount of cytokines
and inflammatory factors, which can act as signals to promote PTX3 release. In line with this
issue, in plasma of patients with shigellosis (infected with S. sonnei) the levels of PTX3 correlate
positively with the severity of symptoms, particularly with high temperature and blood in the
stools being a reliable parameter of severity of shigellosis, just as in conditions like sepsis [49]
and critical infections [50].
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As it seemed that Shigella invasion alone poorly promotes the production of PTX3, we analyzed
PTX3 release in vitro upon Shigella infection. Epithelial cells, macrophages, DCs and neutrophils
that contribute to Shigella-mediated inflammation have all been described as producers of PTX3.
In vitro intestinal cells such as Caco-2 cells do not release PTX3 and only increase their
mRNA expression upon exposure to bacteria and bacterial moieties [51]. Likewise, Shigella-
infected Caco-2 cells did not produce detectable levels of PTX3 (S7A Fig). Moreover, bron-
chial epithelial cells express and produce PTX3 upon TNF-α trigger, but not following bacte-
rial PAMP stimulation (such as LPS) [52]. We could suggest that in natural and experimental
shigellosis, epithelial cells cannot or barely produce PTX3 upon initial bacterial contact. PTX3
is likely to be released only when inflammatory signals like TNF-α and especially IL-1β are
present. Upon inflammatory activation, neutrophils release about 25% of their pre-formed
PTX3 content in lactoferrin granules [53]. In lung sections of infected animals, neutrophils
were strongly immunostained for PTX3. Neutrophils recruited by inflammatory mediators
could constitute a main source of PTX3 upon Shigella invasion under in vivo conditions.
In contrast to epithelial cells, Shigella-infected macrophages and DCs produce PTX3. How-
ever, virulent/invasive shigellae induce lower levels of PTX3 than do non-invasive/avirulent
shigellae in these cells, suggesting that phenotypes associated with invasiveness play a major
role in controlling PTX3 production.
LPS is a main Shigella trigger in macrophages and DCs, eliciting PTX3 production. In contrast
to UPEC-infected cells that secrete PTX3 upon LPS-TLR4/MyD88 activation, both TLR4 medi-
ated pathways, MyD88 and Trif, participate in PTX3 production in Shigella-infected macrophages
and DCs. Involvement of the TriF pathway is evident as the absence of Trif or Irf3 abrogates and
massively reduces the PTX3 release in BMDMs and BMDCs, respectively. The role of IRF3 in
PTX3 production has already been observed in the context of tissue repair and remodeling [54].
In Shigella-infected BMDMs, Irf3 is not involved in TNF-α production, thereby suggesting that
the PTX3 and TNF-α downstream signaling pathways diverge upon LPS-TLR4 activation.
The composition of LPS finely modulates PTX3 production, in accordance with the degree
of acylation. Hypo-acylated LPS derived from intracellular shigellae stimulates a reduced
release of PTX3 with respect to hexa-acylated LPS extracted from bacteria grown under con-
ventional conditions, as also reported for cytokine production [8]. The impact of LPS compo-
sition present on live bacteria on PTX3 and TNF-α yield is particularly evident in human cells.
Under some experimental conditions, LPS composition tuned PTX3 production more finely
than TNF-α production. This result strongly links PTX3 production to LPS composition also
in different physiological and pathological contexts.
In conclusion, at a local level of Shigella infection, PTX3 could tip the balance toward bacte-
rial eradication playing a double role: on the bacterial side, it helps to reduce epithelial cell
invasion, to implement macrophage phagocytosis and to favor complement activity; on the
host tissue side, it contributes to the prevention of the development of the destructive inflam-
mation, which is a main feature of shigellosis. This immune evasion behavior can favor bacte-
rial survival and proliferation, thus allowing tissue colonization during the initial phases of the
disease. We suggest that PTX3 could potentially contribute to the eradication of the infection
by targeting the poorly explored extracellular phase of the invasion process, which can be con-
sidered the “Achille heels” of Shigella invasion process.
Material and methods
Bacterial strains and growth conditions
M90T: wild type S. flexneri strain (serotype 5a); BS176: plasmidless, non-invasive M90T deriv-
ative [55]; M90T ΔipaB: non-invasive T3SS mutant [19]; M90T ΔmsbB1 ΔmsbB2: LPS mutant
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which lacks both copies of the msbB genes (msbB1 and msbB2), each of which encodes the
enzyme myristolyl transferase. M90T ΔmsbB1 ΔmsbB2 carries a hypo-acylated lipid A [8, 38].
M90T-GFP was created by transforming wild type strains with TGI pFpV25.1 vector [56]. The
Shigella sonnei wild type strain has been described by Rossi [57]. Bacteria were routinely grown
in Trypticase soy broth (TSB) (BBL, Becton Dickinson and Co., Cockeysville, MD) or agar
(TSA). TSA containing 100 mg of Congo Red dye (Cr) per liter was used to select virulent clones
of Shigella. Streptomycin (Sm) and ampicillin (Ap) were added to cultures at 100 μg/mL.
For the PTX3 binding assay a Pseudomonas aeruginosa wild type laboratory strain, PAO1
was used as a positive control.
PTX3 binding assay
The procedure was carried out as originally described with minor modifications [12]. A total
of 107 CFU were incubated in 50 μl HBSS (Hank’s Balanced Salt Solution) with 0.5% BSA and
biotinylated PTX3 (50 μg/mL) (1.1 μM,) [15] or biotinylated BSA (70 μg/mL). After 1 h at
room temperature, samples were extensively washed with HBSS. Samples were incubated in
100 μL HBSS with 0.5% BSA with streptavidin-FITC anti-mouse Ig (1:1000) (BD, Pharmin-
gen). Binding was evaluated by fluorescence-activated cell sorting (FACS).
Bactericidal serum assay
Normal human serum (NHS) was produced from buffy coats obtained by the blood bank of
Sapienza University and was collected from 10 healthy adult volunteers (blood donors) with
no history of shigellosis following written informed consent. The blood was allowed to clot,
and the serum was subsequently harvested, pooled, and stored at -70˚C until used. Heat-inacti-
vated serum (HIS) was generated by incubating NHS for 1 h at 56˚C. Exponential phase bacte-
ria were suspended in Dulbecco’s Phosphate-Buffered Saline (DPBS) with Mg2+ and Ca2+ and
incubated at 37˚C for 30 min in the presence of NHS or HIS.
Bacterial survival was calculated as CFU in the presence of NHS/CFU in the presence of
HIS x 100.
HeLa cell infection
HeLa cells (ATCC Cell Biology Collection) were seeded on 6-well plates (8 x 104 cells/mL) and
allowed to adhere for 12 h. An amount of 108 CFU of wild type M90T in early exponential
phase (OD600 0,4–0,6) were incubated in either DMEM (Gibco, Life technologies) only or
with PTX3 (50 μg/mL) or anti-IpaD Ab or BSA (50 μg/mL) or with PTX3 and BSA at the same
time for 1 h at 37˚C and then used to infect HeLa cells at MOI 50. After 60 min, cells were
washed three times with PBS and incubated for an additional 1 or 2 h. Cells were washed three
more times with PBS, detached with trypsine, counted and lysed with deoxycholic acid (0,5%
in H2O). Cell lysate was plated on Congo Red (0,1%) containing TSB agar plates and CFU
were counted after 18 h of incubation.
Bone marrow-derived macrophage (BMDM) and dendritic cell (BMDC)
cultures, stimulation and infection assays
C57BL/6 female mice from Charles River, Calco, Italy, were maintained in a specific patho-
gen-free animal facility of the University of Camerino and euthanized by cervical dislocation.
Myd88-/-, Trif-/-, Irf3-/- or Cd14-/- were a kind gift of Maria Rescigno (Myd88-/-), IFOM-IEO
Campus, Milan, Italy and Francesca Granucci (Trif-/-, Irf3-/- or Cd14-/-), Università degli Studi
di Milano-Bicocca, Milan, Italy. Ptx3-/- were generated as described [12]
PTX3 tips the balance against Shigella infection
PLOS Pathogens | https://doi.org/10.1371/journal.ppat.1007469 December 7, 2018 17 / 27
Wild-type and mutant BMDMs and BMDCs were derived from bone marrow cells col-
lected from five-week-old female mice, as already reported [8] and as detailed as follows.
BMDCs (bone barrow derived dendritic cells) were differentiated for 7 days in RPMI 1640
(Lonza, Italy) containing 10% heat inactivated fetal bovine serum (FBS) (Gibco, Life technolo-
gies), 100 μM non-essential amino acids, 1000 U/mL penicillin and 1000 U/mL streptomycin
(all from Lonza, Italy), supplemented with 30% R1, containing fibroblast produced GM-CSF,
as described [58]. After 7 days, BMDCs were characterized by immunostaining with CD11b,
CD11c, CD80, CD86, MHCII monoclonal antibodies (all from BD Pharmingen, Italy) through
a flow cytometric analysis on a FACSCalibur cytometer (Becton Dickinson,San Jose´, CA,
USA). Data acquisition (104 events for each sample) was performed using CellQuest software
(Becton Dickinson, San Jose´, CA, USA). Analysis was performed with FlowJo software (TreeS-
tar Inc., Ashland, USA).
BMDC infections with S. flexneri strains and S. sonnei were carried out at MOI 10. Infected
BMDCs were incubated for 2 h before washing and adding gentamicin (60 μg/mL) (Gibco).
Cells were incubated for further 1 h, 3 h, 6 h and 18 h post infection (p.i.) and supernatants
were collected and analyzed for PTX3 and TNF-α release. When indicated, cytochalasin D was
added 1 h before infection (0,4 μg/mL) (Invivogen). Alternatively, bacteria were killed by gen-
tamicin (60 μg/mL) treatment for 1 h and added to BMDCs at MOI 10. The supernatants were
then collected for ELISA at different time points (1 h, 3 h, 6 h and 18 h).
For LPS stimulation BMDCs, cells were seeded on 12-well plates (5 x 105 cells/well). LPS
stimulation was carried out with: LPS derived from intracellular shigellae (iLPS), shigellae
grown in TSB medium (aLPS) and M90T ΔmsbB1msbB2 LPS, as described, [8] and commer-
cial E. coli LPS (LPS ultrapure–EB; InvivoGen) at the concentration of 1 and 10 ng/mL for 18
h. Supernatants were collected for ELISA analysis.
BMDMs (bone barrow derived macrophages) were differentiated for 8 days in RPMI 1640
(Lonza, Italy) containing 10% heat inactivated FBS, 100 μM non-essential amino acids, 1 mM
sodium pyruvate, 1000 U/mL penicillin and 1000 U/mL streptomycin (all from Lonza, Italy),
supplemented with 30% L929 fibroblast supernatant, containing M-CSF (Macrophage-Colony
Stimulating Factor). F4/80 and CD11b double-positive cells were considered as differentiated
BMDMs and used in the experiments.
For stimulation assay, differentiated BMDMs were seeded on 24-well plates (5 x 105 cells/
well) and exposed to different concentrations (1, 10, or 100 ng/mL) of M90T iLPS, aLPS, and
M90T ΔmsbB1msbB2 LPS, as described, [8] and commercial E. coli LPS (LPS ultrapure–EB;
InvivoGen). Stimulation was carried out for 6 h and 18 h. Cell supernatants were recovered
and stored at -20˚C to be used in the ELISA assay.
BMDM infections assay with S. flexneri and S. sonnei strains were performed as reported
[8] with minimal differences. Briefly, bacteria were used at MOI 10 on cells pre-treated or not
for 4 h with Shigella iLPS, aLPS, ΔmsbB1 ΔmsbB2 LPS and E. coli LPS at the concentration of
10 ng/mL. Infected BMDMs were incubated at 37˚C for 1 h, washed twice with PBS, and
treated with gentamicin (60 μg/mL) for 3 h. At this time, supernatants were analyzed for PTX3
and TNF-α release.
Human macrophage and dendritic cell cultures, stimulation and infection
assays
PBMCs (peripheral blood mononuclear cells) were isolated from buffy coats obtained by the
blood bank of Sapienza University from healthy adult volunteers (blood donors) following
written informed consent.
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Macrophages
PBMCs (peripheral blood mononuclear cells) were obtained from blood of healthy adult vol-
unteers (blood donors), through a density gradient. CD14+ monocytes were isolated using the
MACS microbead system (Miltenyi Biotec, Bergisch Gladbach, Germany). The monocytes
were cultured for 6 days in RPMI 1640 (Lonza) supplemented with 10% heat-inactivated FBS
(Euroclone Fetal Bovine Serum, GE Healthcare Life Sciences,U.S.), 100 μM non-essential
amino acids, 1 mM sodium pyruvate, 1000 U/ml penicillin and 1000 U/mL streptomycin (all
from Lonza, Italy) and 50 ng/mL GM-CSF (Granulocyte-Macrophage Colony-Stimulating
Factor) (Miltenyi Biotec) to obtain human macrophages.
Stimulation assays: MoMs (peripheral blood monocyte-derived macrophages) were seeded
in 24-well plates (2,5 x 105 cells/well), exposed to 1 ng/mL of LPS derived from intracellular
shigellae (iLPS), shigellae grown in TSB medium (aLPS), Shigella ΔmsbB1 ΔmsbB2 LPS and
commercial E. coli LPS (LPS ultrapure–EB; InvivoGen) and incubated for 12 h. Cell superna-
tants were recovered and processed for ELISA.
MoM infection assays with Shigella M90T strain, its derivatives BS176 and M90T ΔmsbB1
ΔmsbB2 strains, and S. sonnei strain were performed using MOI 0,1 on cells pretreated or not
with Shigella iLPS, aLPS, ΔmsbB1msbB2 LPS and commercial E. coli LPS (LPS ultrapure–EB;
InvivoGen) for 4 h (0,1 ng/mL). Infected macrophages were incubated at 37˚C for 1 h, washed
twice with PBS solution, and treated with gentamicin (60 μg/mL) for 3 h. Supernatants were
recovered and evaluated by ELISA. For infection with PTX3 treated bacteria, shigellae were
incubated with PTX3 or BSA (50 μg/mL) or a polyclonal rabbit anti-IpaD antibody (5 μL) (gift
of Abdel Allaoui) for 1 h at 37˚C. MOI 5 was used for 2 h. MoDCs were infected with bacteria
at MOI of 10.
MoM death evaluation: 108 M90T were opsonized with recombinant PTX3 (50 μg/mL),
BSA (50 μg/mL) or anti-IpaD Ab or nothing for 1 h at room temperature and then used to
infect MoMs at MOI 5 for 2 h before evaluation of lactate dehydrogenase (LDH) release in
supernatant. LDH was measured through the CytoTox 96 Non-Radioactive Cytotoxicity Assay
kit (Promega, USA), according to manufacurer’s instruction. To adjust for spontaneous lysis,
% release was calculated as follows: (Release in sample–release from non-infected cells)/(maxi-
mum release–release from non-infected cells) � 100.
Phagocytosis Assay: percentage of bacterial internalization by MoMs was evaluated through
cytofluorimetric analysis. CD14 was used as MoM marker, and cells positive for both GFP and
CD14 were considered infected cells. Data acquisition (104 events for each sample) was per-
formed using CellQuest software (Becton Dickinson, San Jose´, CA, USA). Analysis was per-
formed with FlowJo software (TreeStar Inc., Ashland, USA).
Dendritic cells. MoDC (peripheral blood monocyte-derived dendritic cell) culture, stimu-
lation and infection.
PBMCs were obtained from blood of healthy adult volunteers (blood donors), through a
density gradient as above. CD14+ monocytes were isolated using the MACS microbead system
(Miltenyi Biotec, Bergisch Gladbach, Germany). The monocytes were cultured for 5 days in
RPMI 1640 (Lonza) supplemented with 10% heat-inactivated FBS (HyClone Fetal Bovine
Serum, GE Healthcare Life Sciences,U.S.), 100 μM non-essential amino acids, 1000 U/mL pen-
icillin and 1000 U/mL streptomycin (all from Lonza, Italy), 20 ng/mL IL-4 and 50 ng/mL
GM-CSF (both Miltenyi Biotec) to obtain immature human dendritic cells. MoDCs were char-
acterized by immuno-staining with CD11c, CD14 and CD80 (all from BD Pharmingen, Italy)
through a flow cytometric analysis.
For MoDC stimulation, MoDCs were collected, seeded on 12-well plates (5 x 105 cells/well)
and exposed to 10 ng/mL of iLPS, aLPS, M90T ΔmsbB1 ΔmsbB2 LPS and E. coli LPS for 12 h.
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For MoDC infections, cells were seeded at 5 x 105 cells/well on the morning of infection.
Exponential phase bacteria were added at MOI 10 directly to the wells containing MoDCs.
Plates were centrifuged for 5 min at 300 x g and incubated at 37˚ C for 2 h. Fresh medium con-
taining gentamycin (60 μg/mL) was added, and cells were incubated for further 1 h, 3 h, 6 h
and 18 h.
Intranasal infections of mice
Five-week-old (18–20 gr) C57BL/6 female wild type (Charles River, Calco, Italy) or Ptx3-/-
mice were maintained in a specific pathogen-free animal facility of the University of Camer-
ino. For all the infections, mice were anesthetized intramuscularly with 50 μL of a solution
containing Zoletil (1 mg) (Virbac, Carros, France) and Xilor (2%) (BIO 985, San Lazzaro,
Italy) and inoculated intranasally with 20 μL of 0.9% NaCl suspensions containing 3 x 108
CFU of S. flexneri M90T strain [47,6].
When required, infected mice (wild type) were treated once per day for 3 days with recom-
binant PTX3 (10 μg/mouse intraperitoneally, 0,5 mg/Kg, corresponding to 11 μM) or with
sterile saline and examined daily to evaluate the survival during 8 days (n = 22 for M90T-
infected-mice, n = 19 for M90T-infected and treated-mice, n = 10 for non-infected PTX3-
treated mice, in three separate experiments), or euthanized at 3 days post-infection (n = 10 for
M90T-infected-mice and n = 11 for M90T-infected and treated-mice, n = 10 for non-infected
PTX3-treated mice, in three separate experiments). At this time, bronchoalveolar lavages
(BAL) were performed and BALs were used for cytokine analysis. Lungs were removed,
homogenized and plated on TSA plates (1 lung per mice) or analyzed for relevant cytokines or
alternatively fixed in formalin. Consecutive sections from the middle of the five lung lobes
were used for histological and immunohistochemical examination. In the experiments using
Ptx3-/- mice survival was analyzed up to 8 days p.i. (n = 30, in three separate experiments) and
their lungs were processed to assess the bacterial load and cytokine production at 48 h p.i.
(n = 10 Ptx3-/-; mice n = 13 wild type), in three separate experiments).
Histopathology and Immunochemistry studies
Lungs samples were fixed in 4% formaldehyde for 18 h at room temperature and treated for
histopathological and immunochemistry studies as described [6]. The samples were gradually
dehydrated and then embedded in paraffin. The specimens were cut in 3-μm-thick slices and
stained with hematoxylin-eosin (Carlo Erba) or immunostained. Immunohistochemistry was
performed by using the following antibodies: rabbit polyclonal anti-human PTX3 [14]. and
mouse monoclonal anti-PMNs (MA5-12607, clone BM-2, ThermoFisher Scientific, USA). The
sections were incubated with the secondary antibodies (1:200) for 45 minutes and then exam-
ined blindly and scored by a pathologist.
ELISA assay
Cytokine and chemokine concentrations were determined by commercially available ELISA
kits (Duo Set R&D systems). The absorbance was measured on a LT-4000 Microplate reader
(Labtech) (Hercules, CA, USA).
LPS preparations
The LPSs used in this study are the same as those used by Paciello [8]. Refer to this article for
relevant information about the experimental procedures for LPS extraction and purification.
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Measurements of PTX3 levels in plasma samples collected from cases of
shigellosis and healthy controls
31 patients in the acute stage (0–7 days after onset) of culture-proven S. sonnei shigellosis were
recruited for the study. They included 31 children aged 0.2–10 years and one adult. The control
group included 19 healthy subjects, 11 adults and 8 children aged 0.5–14 years. Signed informed
consent was obtained from the parents of all participating children and from all participating
adults. Participants or their parents completed a questionnaire with personal data and details
regarding symptoms and onset of disease. Blood samples were collected using EDTA tubes (Gei-
ner Bio-One). Plasma was separated and stored at -80 oC until assayed.
Statistical analysis
Data was presented as mean ± S.D., and the number of independent experiments is indicated
in each legend of the figures. Statistics were performed with GraphPad Prism and data analysis
was carried out as follow: Mantel-Cox test was used to compare survival curves; non-paramet-
ric Mann-Whitney U test for CFU counts and cytokine/chemokines quantification in mice;
Student’s t-test for PTX3 and TNF-α release in cell cultures and paired t-test for PTX3 quanti-
fication in plasma of patients. P< 0.05 was considered significant.
Ethics statement
Mice experiments were conducted according to the ethical requirements of the Animal Care Com-
mittee of the University of Camerino (study protocol No 17/2012) upon approval of the Ministero
della Salute, Direzione Generale della Sanità Animale e dei Farmaci Veterinari, Ufficio VI (Bene-
ssere animale), in line with the Guidelines laid down by the European Communities Council (86/
609/ECC) for the care and use of laboratory animals. The study involving shigellosis patients and
controls has been has been approved by the IRBs of Hillel Yaffe Medical Center and the Israel Min-
istry of Health (Study protocol No. AH-382-11). Written signed informed consent was obtained
from the parents of all participating children and from all participating adults. PBMCs (peripheral
blood mononuclear cells) were isolated from buffy coats obtained by the blood bank of Sapienza
University from healthy adult volunteers (blood donors) following written informed consent.
Supporting information
S1 Fig. Opsonization of S. flexneri by PTX3 and downstream effects on HeLa cells and
macrophages. (A): Dose response of PTX3 opsonization on HeLa cells invasion. S. flexneri
M90T was incubated for 1 h with either recombinant PTX3 (0.05, 0.5, 5 or 50 μg/mL;
0,0011 μM, 0,011 μM, 0,11 μM, 1,1 μM respectively), anti-IpaD Ab (5 μL), BSA (both at 50 μg/
mL) or medium and used to infect HeLa cells at a multiplicity of infection (MOI) of 50. The
number of bacteria per infected cell was evaluated at 1 h and 2 h of incubation post-infection;
(B and C): Dose response of PTX3 opsonization on infected human macrophages (MoMs).
(B) Bacterial internalization in MoMs. M90T (expressing GFP) opsonized as in (A) was used
to infect MoMs at MOI 5 for 2 h p.i. (C): Lactate dehydrogenase (LDH) release in supernatant
of MoMs treated as above. Histograms report the mean values (± SEM) of three independent
experiments. (� p< 0.05; �� p< 0.01; ��� p< 0.001 with Student’s t-test).
(TIF)
S2 Fig. Lung features and histological analysis of animals infected with M90T or infected
with M90T and treated with PTX3 or uninfected and treated with PTX3. (Top): Macroscopic
aspect of lungs. (Bottom): (A, D, G) Photomicrographs of lung lesions of M90T-infected mice.
Note: (A) the absence of functional airspaces, atelectasis and diffuse pulmonary consolidation
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areas; (D) a mixed inflammatory infiltrate extending across the lung (arrows) and damaged alveo-
lar spaces; (G) a scant BALT activation. (B, E, H) Lungs of mice infected with M90T and treated
with PTX3 (10 μg). Note: (B) the preserved pulmonary airspaces and few small areas with a mild
inflammatory infiltrate; (E) a moderate inflammation in the absence of severe bronchoalveolar
lesions; (H) BALT activation close to the bronchioles (arrows). (C, F, I) lung section of uninfected
animals treated with PTX3 (10 μg). Note: (C, F) the physiological conditions of lung tissue where
interstitial texture is well preserved; (I) a moderate BALT activation (arrow). Original magnifica-
tion: A-C, 2X, bars 400 mm, D-H, 10X, bars 200 mm I, 20X, bars 50 mm.
(TIF)
S3 Fig. Immunohistochemical staining of PTX3 in lung sections of animals infected with
M90T or infected with M90T and treated with PTX3 or uninfected and treated with PTX3.
Sections of tissues infected with M90T (a) of PTX3-treated infected animals (b) and in tissues
of uninfected animals treated with PTX3 (c).
Anti-PTX3 immunohistochemical staining; counterstain: Meyer’s Haematoxylin; Original
magnification: 10X, bars 200 mm.
(TIF)
S4 Fig. TNF-α release by C57BL/6 BMDCs and MoDCs infected with S. flexneri. BMDCs
(A) and MoDCs (B) were infected using a gentamycin protection assay with M90T and BS176
at MOI 10 during 1 h, 3 h, 6 h and 18 h post-infection (p.i.) (on); BMDCs from (C) Myd88-/-
and Cd14-/- and (D) Trif-/- and Irf3-/-defective mice were infected with M90T and BS176 at
MOI 10 for 12 h of incubation p.i. (E) BMDCs were stimulated with 1 ng and 10 ng of LPS
derived from intracellular shigellae (iLPS), shigellae grown in TSB medium (aLPS), M90T
ΔmsbB1 ΔmsbB2 LPS and purified commercial E. coli LPS for 12 h; (F) BMDCs were infected
with M90T, BS176 and M90T ΔmsbB1 ΔmsbB2 at MOI 10 for 1 h, 3 h, 6 h and 18 h p.i (o/n).;
(G) MoDCs were stimulated with 10 ng of iLPS, aLPS, M90T ΔmsbB1msbB2 LPS and with E.
coli LPS for 12 h. (H) MoDCs were infected with M90T, BS176 and M90T ΔmsbB1 ΔmsbB2 at
MOI 10 for 1 h, 3 h, 6 h and 18 h (o/n).
TNF-α release in supernatants of cells was determined by ELISA. Data reported are the mean val-
ues (± SEM) of three independent experiments. Bars represent the mean values ± S.D. from three
independent experiments. NI: Not infected; NS: Not stimulated; ΔmsbB: M90T ΔmsbB1 ΔmsbB2.
Significant difference is indicated as follows: � p< 0.05, �� p< 0.01, and ���p< 0.001 in the Stu-
dent’s t-test.
(TIF)
S5 Fig. TNF-α production by S. flexneri infected C57BL/6 BMDMs and MoMs. TNF-α
release in supernatant of (A) BMDMs after infection using a gentamycin protection assay with
M90T and BS176 (MOI 10), at 1 h, 3 h and 6 h p.i.; (B) BMDMs stimulated with 10 ng/mL of
iLPS, aLPS, M90T ΔmsbB1 ΔmsbB2 LPS and E. coli LPS for 4h, and then infected with M90T
(MOI 10) for 3 h p.i.; (C) BMDMs stimulated with 10 ng/mL of iLPS, aLPS and E. coli LPS, at
6 h and 18 h (o/n); (D) BMDMs stimulated with 10 ng/mL of iLPS, aLPS, ΔmsbB1 ΔmsbB2
LPS and commercial E. coli LPS during 4h, and then infected with M90T or M90T ΔmsbB1
ΔmsbB2 (MOI 10) for 3 h p.i.; (E) MoMs infected with M90T, M90T ΔmsbB1 ΔmsbB2 or
BS176 (MOI 0,1) for 3 h p.i.; (F) MoMs after stimulation with 0,5 ng/mL of iLPS, aLPS and E.
coli LPS for 12h. (G-H) BMDMs from wild type, and Cd14-/- and Myd88-/- (G) and Trif-/-,
Irf3-/- (H) defective mice were pre-stimulated and infected with M90T as described above;
Graphs show the mean ± SD of triplicate wells and are representative of three independent
experiments (� p< 0.05, �� p< 0.01, and ���p< 0.001 in the Student’s t-test).
(TIF)
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S6 Fig. PTX3 and TNF-α production by S. sonnei infected dendritic cells or macrophages.
PTX3 (A) and TNF-α release (D) in supernatants of BMDCs infected with S. flexneri M90T
and S. sonnei (MOI 10) at 1 h, 3 h, 6 h and 18 h p.i. (o/n); PTX3 (B) and TNF-α release (E) in
supernatants of MoDCS infected with S. flexneri M90T and S. sonnei (MOI 10) at 1 h, 3 h, 6 h
and 18 h p.i. (o/n); PTX3 release (C) and TNF-α release (F) in supernatants of BMDMs after
infection with S. flexneri M90T and S. sonnei (MOI 10) at 1 h, 3 h, 6 h incubation p.i.; PTX3
release (G) and TNF-α release (H) in supernatants of BMDMs stimulated with 10 ng/ml of
LPS derived from intracellular shigellae (iLPS), shigellae grown in TSB medium (aLPS), Shi-
gella ΔmsbB1 ΔmsbB2 and LPS and commercial E. coli LPS for 4 h, and then infected with S.
flexneri M90T or S. sonnei (MOI 10) for 3 h p.i.; PTX3 release (I) and TNF-α release (J) in
MoMs infected with Shigella M90T and S. sonnei (MOI 0,1) after 3 h of incubation p.i.
PTX3 and TNF-α release were measured through ELISA. NI: Not infected; NS: Not stimulated;
ΔmsbB: M90T ΔmsbB1 ΔmsbB2.
Graphs show the mean ± SD of triplicate wells and are representative of three independent
experiments (� p< 0.05, �� p< 0.01, and ���p< 0.001 in the Student’s t-test).
(TIF)
S7 Fig. PTX3 and CXCL8 production by M90T-infected Caco-2 cells. PTX3 (A) and CXCL-
8 (B) release in M90T-infected Caco2 cells following 4 h and 18 h of incubation p.i. (o/n).
Caco2 cells stimulated with 10 ng/mL of purified commercial E. coli LPS and with 300 ng/mL
of Pam3CSK4 (from Invivogen) were used as positive control. NI Caco2: not infected/not
stimulated Caco2 cells.
(TIF)
S1 Table. Histopathological scores for lesions in lungs from mice infected with S. flexneri
5a strain M90T. N = 10.
a Degree of inflammation was scored as follow: O-none, 1-milde, 2-moderate, 3-severe.
b Inflammation type: presence of acute and chronic inflammatory cells scored as cell per high-
power field (HPF) at x400 magnification (0� 5 cells; 1 = 5–49 cells; 2 = 50–99 cells; 3� 100).
c The extension of the process was classified in diffuse intraluminal and interstitial on the basis
of the field range.
d Degree of activation of broncho-alveolar associated lymphoid tissue (i.e. presence and size of
clear center and follicular structuration of BALT aggregates.
e Degree of thickening of interalveolar septa due to inflammatory oedema.
f Degree of bronchiolar epithelium desquamation and necrosis.
g Degree of bronchial involvement.
h Degree of pleural involvement.
i The percentage of lung involved was scored as follow: 0–25% focal lesion of inflammed areas,
25–50% various areas of inflammed parenchyma, 50–75% almost 2/3 of lung’s lobe involved,
75–100% lung entirely envolved.
(TIF)
S2 Table. Manifestation of the disease and level of PTX3 among S. sonnei shigellosis
patients. All relevant information are on the table.
(TIF)
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